Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) — Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (“HAE”) and acquired angioedema due to C1 inhibitor deficiency (“AAE-C1INH”), announced today the pricing of an […]